Publications

All publications
June 15, 2016

Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging Cell.

Written and published by Biogerontology Research Foundation staff in collaboration with the Buck Institute for Research on Aging, Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Institute of Biology of Komi Science Center of Ural Branch of Russian Academy of Sciences, Moscow Institute of Physics and Technology, Rogachev FRC Center for Pediatric Hematology, Oncology and Immunology and 5Institute for Systems Analysis, Russian Academy of Sciences.

Developing criteria for evaluation of geroprotectors as a key stage toward translation to the clinic. Aging Cell. 2016 Jun;15(3):407-15.

Moskalev A(1,2,3), Chernyagina E(3), Tsvetkov V(3,4), Fedintsev A(2), Shaposhnikov M(1), Krut'ko V(5), Zhavoronkov A(2,6,7), Kennedy BK(8).

(1) Engelhardt Institute of Molecular Biology of Russian Academy of Sciences, Moscow, 119991, Russia.

(2) Institute of Biology of Komi Science Center of Ural Branch of Russian Academy of Sciences, Syktyvkar, 167982, Russia.

(3) Moscow Institute of Physics and Technology, Dolgoprudny, 141700, Russia.

(4) The Research Institute for Translational Medicine, Pirogov Russian National Research Medical University, Moscow, 117997, Russia.

(5) Institute for Systems Analysis, Russian Academy of Sciences, Moscow, 117312, Russia.

(6) D. Rogachev FRC Center for Pediatric Hematology, Oncology and Immunology, Samory Machela 1, Moscow, 117997, Russia.

(7) The Biogerontology Research Foundation, 2354 Chynoweth House, Trevissome Park, Blackwater, Truro, Cornwall, TR4 8UN, UK.

(8) Buck Institute for Research on Aging, Novato, CA, 94945, USA.

Abstract: In the coming decades, a massive shift in the aging segment of the population will have major social and economic consequences around the world. One way to offset this increase is to expedite the development of geroprotectors, substances that slow aging, repair age-associated damage and extend healthy lifespan, or healthspan. While over 200 geroprotectors are now reported in model organisms and some are in human use for specific disease indications, the path toward determining whether they affect aging in humans remains obscure. Translation to the clinic is hampered by multiple issues including absence of a common set of criteria to define, select, and classify these substances, given the complexity of the aging process and their enormous diversity in mechanism of action. Translational research efforts would benefit from the formation of a scientific consensus on the following: the definition of 'geroprotector', the selection criteria for geroprotectors, a comprehensive classification system, and an analytical model. Here, we review current approaches to selection and put forth our own suggested selection criteria. Standardizing selection of geroprotectors will streamline discovery and analysis of new candidates, saving time and cost involved in translation to clinic.

Press enquiries
All enquiries should be directed to
info@bg-rf.org.uk